Introduction
Breast cancer (BC) comprises a heterogeneous group of extraordinarily hormone-dependent tumors that are diverse in behavior, response to therapy, and outcome. The majority of BC patients (30-50%) present with locally advanced disease [1] and are ideally managed by neoadjuvant chemotherapy (NACT) with the aim of upfront local and systemic control.
In recent years, gene expression profiling has been used to classify BC into 5 major subtypes (luminal A, luminal B, HER2 overexpressing, basal-like, and normal-like subtypes) with distant clinical outcomes [2] [3] [4] [5] . However, a panel of immunohistochemical (IHC) markers provides clinicians with a cost-effective valid alternative to genotyping assays [6] . Although extensively reported in Western studies [7] [8] [9] [10] , data from South-Asian countries (especially India) remain limited, with anecdotal literature on the relationship between molecular subtypes as defined by IHC and clinicopathological characteristics.
Anti-estrogen therapy and targeted therapy with trastuzumab have established their role in management of BC. Triple-negative BC (TNBC: estrogen receptor (ER), progesterone receptor (PR) and HER-2 neu negative) represents a unique biology that lacks any effective targeted therapies, so that a search for more biomarkers is necessary. Androgen receptor (AR) is an emerging biological marker in the field of breast carcinogenesis. Published data have indicated the presence of AR in BC tissues, most commonly in luminal A and B subtypes but also in approximately one-third of TNBC cases [11] [12] [13] . AR expression has also been reported in almost 50% of ER-negative BC patients [14, 15] and as sole receptor in 25% of metastatic BC [16] . Nevertheless, the role of AR as a predictive or prognostic factor has not been well documented to date [13] .
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This current study was conducted to investigate the prevalence of AR positivity in invasive BC in an Indian cohort, the association of AR with various clinicopathological factors, established prognostic markers and molecular subtypes, and the role of AR in predicting response to NACT. 
Methods

Study Subjects and Inclusion Criteria
IHC Staining of AR, ER, PR and HER2/neu and Subtype Definition
We evaluated AR, ER, PR and HER2/neu expression in specimens from formalin-fixed, paraffin-embedded Tru-cut biopsy tissue using IHC. Primary antibodies for AR (monoclonal, clone F39.4.1; Biogenex, diluted 1: 50), ER (monoclonal, clone 6F11; Novocastra, 1: 50 dilution), PR (monoclonal, clone PgR 312/2; Novocastra, 1: 50 dilution) and HER2/neu (polyclonal; Dako, diluted 1: 500) were used.
The thresholds suggested by the 2011 ASCO/CAP guidelines for ER/PR and the 2007 ASCO/CAP guidelines for HER2/neu interpretation were used. 2011 ASCO/CAP guidelines were applied for AR and considered at least 1% nuclear staining of any intensity (1+ to 3+) as a positive AR assay ( fig. 1) .
In this study, we opted for a simple classification based on the expressions of ER, PR and HER2 [6, 17] . BC was classified into 4 subtypes: luminal A (ER+ and/or PR+, HER2-); luminal B (ER+ and/or PR+, HER2+); triple negative (ER-, PR-, HER2-) and HER2/neu enriched (ER-, PR-, HER2+).
Assessing Response to NACT
Patients with locally advanced BC (stage IIIb or above) were subjected to NACT (FEC followed by docetaxel chemotherapy: 5-fluorouracil 500 mg/m intravenously (IV) day 1, epirubicin 100 mg/m IV day 1, cyclophosphamide 500 mg/m IV day 1, cycled every 21 days for 3 cycles; followed by docetaxel 100 mg/m IV day 1, cycled every 21 days for 3 cycles) to downstage the tumor. For assessing the response, patients were evaluated on the basis of WHO clinical response criteria; first prior to 1st cycle and re-evaluated after completion of 4th cycle of chemotherapy. Patients showing partial or complete response were grouped as 'responders', whereas progressive or stable disease was grouped as 'non-responders'.
Statistical Analysis
All data were analyzed using the SPSS 16.0 statistical software package. The chi square and Fisher's exact probability tests were used to analyze the differences between qualitative data. p values below 0.05 were considered significant.
Results
Patient and Treatment Characteristics
Of 131 BC patients, 116 fulfilled the inclusion criteria and were assessed. The mean age of patients at the time of presentation/diagnosis was 47.6 ± 10.1 years (range 20-77 years, median 48 years); 20 were diagnosed with BC before the age of 35 (mean age 31.8 ± 4.4 years; median 34 years) and were considered as 'young age'.
Histologically, all patients had infiltrating ductal carcinoma, not otherwise specified (IDC-NOS). Since in majority of patients, core tissue biopsy was performed using Tru-cut as a part of triple assessment, grade was not commented in the pathological report. Table 1 shows the correlations between AR expression and clinicopathological factors. AR was expressed in 65 patients (56%). AR expression showed negative correlation with overall stage (p < 0.03) and axillary lymph node status (p < 0.04). No statistically significant association of AR expression was observed with age or tumor size. 
Relationship between AR Status and Clinicopathological Data
Relationship between AR Status and Other Hormonal Markers
Relationship between AR Status and BC Subtypes
Maximum positivity with significant association was shown with luminal A subtype (77.8%). Even TNBC showed positivity for AR (30%). In particular, in 'young' BC patients the AR expression was increased among all subtypes including hormone receptornegative subgroups.
Relationship between AR Status and Response to NACT
Among patients who were offered NACT, the majority (47; 65.3%) showed partial response to chemotherapy, with 12 patients (16.7%) showing complete response. AR expression was higher in responders as compared to non-responders (p = 0.218). 24 of 30 patients (80%) with TNBC were given NACT, of whom 7 (29.1%) were AR positive. AR-positive TNBC showed a better response to NACT since 5 of these 7 (71%) were partial or complete responders compared with 3 of the 17 (17.6%) AR-negative TNBC patients. 
Discussion
Expression of ER, PR and HER2/neu as predictive and/or prognostic markers in BC development has led to a paradigm shift in treatment approach to targeted chemotherapy regimens [18] [19] [20] [21] . AR is highly expressed in all BCs (60-70%), irrespective of ER status [22] [23] [24] , but its definite role remains to be established. Various publications document the AR expression as ranging from 43 to 75% in different cohorts [12, [25] [26] [27] [28] [29] . Moinfar et al. [28] found 60% of all invasive carcinomas and 46% of ER-negative invasive carcinomas to be AR positive. In a study from India, Mishra et al. [30] reported the prevalence to be 40%. The results of our study are in agreement with these publications, showing that AR was expressed in 56% of invasive BC cases. It has also been shown that AR is more frequently expressed in particular histological types of BC, more commonly in IDC-NOS, and with less frequency in other histopathological types [30, 31] . Our study showed that more than half of patients with IDC-NOS expressed AR. These results were somewhat limited in our study since all patients showed IDC-NOS on histopathology. Our results show that AR expression is associated with lower axillary nodal burden and early AJCC stage. These findings are supported by previous studies indicating that AR expression is related to good prognostic factors, including lower histological grade, smaller tumor size and negative nodal metastasis [32] [33] [34] . The expression was higher in young age and early (T2 and T3) tumor size, but relation of AR with age and tumor size was statistically insignificant. Another limitation of our study was that we did not determine the relationship with grade and Ki67 proliferation index.
In the present work AR expression was also associated with ER and PR positivity (good prognostic factors), in accordance with Park et al. [25] and Ana et al. [26] . However, a significant percentage of ER-and PR-negative tumors showed AR positivity, which has also been reported by Seung et al. [32] and Ana et al. [26] . This information may represent the independent expression of AR in BC and also demonstrate that the presence of AR expression in ERnegative tumors has a particular prognostic significance. AR positivity did not significantly correlate with loss of HER2/neu expression, with HER2/neu-enriched ER/PR-negative tumors showing AR positivity in 42.4%. Micello et al. [35] reported a 77% expression rate in HER2-positive BC. This observation may be used as a good additional target therapy for this subgroup of patients. Laboratory studies have shown inhibitory roles of androgens analogues on ER-negative/AR-positive cells lines. Similar approaches can be used for ER-negative/AR-positive BC as an adjunctive therapy [27] .
In TNBC, chemotherapy is the main adjuvant treatment with an inferior survival. New biomarkers and additional effective treatment strategies need to be explored to improve prognosis in this subset of patients. Safarpour et al. [36] in a recent analysis of AR as a routine assessment in BC tabulated 22 studies reporting the percentage of TNBC in range of 7-60%. These TNBC were mainly of high histological grade, showed a high mitotic index, and were found more frequently in premenopausal women. Xiang et al. [33] showed that TNBC could be divided into a good and a poor prognosis subtype according to AR status. Since AR is expressed in large proportion of TNBC, it might have a role as a prognostic marker and a therapeutic target in this subgroup [18] . In our study, 30% of TNBC cases showed AR positivity. Collins et al. [37] in a Nurse Health study reported that, despite being considered hormonally unresponsive, 32% of basal-like cancers expressed AR. Sa- farpour et al. [36] , while highlighting the fraction of tumors with positive AR among TNBC cases (6.6-75%), made a startling observation that only a fourth of the studies they discussed had used the most recent ASCO/CAP guidelines. If a threshold of 1% were used, the percentage of AR-positive cases would increase and at least these TNBC could also form a subset for targeted therapy. Exploring role of AR expression in predicting response to NACT in locally advanced BC, this study showed that AR was more expressed in patients who were good clinical responders. Mishra et al. [30] and Chintamani et al. [38] have documented that AR status predicts response to chemotherapy in the neoadjuvant setting, and AR can serve as independent predictor of response to NACT.
The prevalence of hormone receptor-positive BC in Asian countries has been found to be lower than the Western world. Western studies have reported 70-80% ER and 60-70% PR expression in BC, respectively [39] [40] [41] [42] . In Indian cohort, Desai et al. [43] documented a prevalence of 32.6% for ER-positive and 46.1% for PR-positive BC. A recent study from Mumbai has also showed that hormone receptor expression in India is lower compared to the West [44] . A study from the northern part of India showed that HER2/neu overexpression is higher (46.37%) in comparison to 25-30% shown in most Western literature [45] . Our study results correlate with the reported literature and highlight the fact that, in India, BC stands apart in terms of clinicopathological features from the Western world.
In conclusion, AR is expressed in a significant percentage of BC cases. AR is also associated with a lower disease burden and favorable established prognostic markers. In addition, AR is expressed in a significant number of TNBC and HER2/neu-positive cancers, and these particular ER-negative patients may benefit from an additional targeted therapy. AR may also be utilized as a predictor of response to NACT, especially in country such as India where the load of locally advanced BC is high.
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